Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker NTLA · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 5, 2026 | A Phase 3 Study of NTLA-2001 in ATTRv-PN NCT06672237 · Neuromuscular Disease, Neuromuscular Diseases (NMD) nexiguran ziclumeran, Normal Saline as Placebo | NTLA Intellia Therapeutics | Phase 3 | Active, not recruiting was recruiting | 67 | Jul 2027 | Registry ↗ |
| Nov 4, 2026 | MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiom… NCT06128629 · Transthyretin Amyloidosis (ATTR) With Cardiomyopathy NTLA-2001, Placebo | NTLA Intellia Therapeutics | Phase 3 | Recruiting | 1,200 | Dec 2027 | Registry ↗ |
| Oct 8, 2026 | HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE) NCT06634420 · Hereditary Angioedema NTLA-2002, Normal Saline IV Administration | NTLA Intellia Therapeutics | Phase 3 | Active, not recruiting | 80 | Feb 10, 2026 | Registry ↗ |
| Sep 25, 2026 | NTLA-2002 in Adults With Hereditary Angioedema (HAE) NCT05120830 · Hereditary Angioedema Biological NTLA-2002, Normal Saline IV Administration | NTLA Intellia Therapeutics | Phase 1/2 | Active, not recruiting | 37 | Apr 4, 2024 | Registry ↗ |
| Aug 3, 2026 | Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001 NCT05697861 · Transthyretin-Related (ATTR) Familial Amyloid Polyneuropath… | NTLA Intellia Therapeutics | — | Enrolling by invitation | 72 | Mar 2038 | Registry ↗ |
| Jan 30, 2026 | Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Pati… NCT04601051 · Transthyretin-Related (ATTR) Familial Amyloid Polyneuropath… NTLA-2001 | NTLA Intellia Therapeutics | Phase 1 | Completed | 72 | Sep 12, 2025 | Registry ↗ |
| Nov 28, 2025 | Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002 NCT06262399 · Hereditary Angioedema | NTLA Intellia Therapeutics | — | Enrolling by invitation | 100 | Apr 2040 | Registry ↗ |
| Jan 17, 2025 | NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease NCT06622668 · Lung Disease, Pulmonary Disease Biological NTLA-3001 | NTLA Intellia Therapeutics | Phase 1/2 | Withdrawn | 0 | Jan 9, 2025 | Registry ↗ |
| Dec 28, 2023 | Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia NCT05066165 · Acute Myeloid Leukemia Arm 1: NTLA-5001, Arm 2: NTLA-5001 | NTLA Intellia Therapeutics | Phase 1/2 | Terminated | 6 | Jul 21, 2022 | Registry ↗ |
9 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 9:06 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances